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abstract
PURPOSE In the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy
with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients with
platinum-sensitive, recurrent ovarian cancer who had a response to their last platinum-based chemotherapy.
The objective of the study was to assess the clinical benefit and patient-reported outcomes in patients who had
a partial response (PR) and complete response (CR) to their last platinum-based therapy.
PATIENTS AND METHODS A total of 553 patients were enrolled in the trial. Of 203 patients with a germline BRCA
mutation (gBRCAmut), 99 had a PR and 104 had a CR to their last platinum-based therapy; of 350 patients
without a confirmed gBRCAmut (non–gBRCAmut), 173 had a PR and 177 had a CR. Post hoc analyses were
carried out to evaluate safety and the risk of progression in these patients according to gBRCAmut status and
response to their last platinum-based therapy. Ovarian cancer–specific symptoms and quality of life were
assessed using the Functional Assessment of Cancer Therapy–Ovarian Symptom Index.
RESULTS Progression-free survival was improved in patients treated with niraparib compared with placebo in
both the gBRCAmut cohort (PR: hazard ratio [HR], 0.24; 95% CI, 0.131 to 0.441; P , .0001; CR: HR, 0.30;
95% CI, 0.160 to 0.546; P , .0001) and the non–gBRCAmut cohort (PR: HR, 0.35; 95% CI, 0.230 to 0.532;
P , .0001; CR: HR, 0.58; 95% CI, 0.383 to 0.868; P 5 .0082). The incidence of any-grade and grade 3 or
greater adverse events was manageable. No meaningful differences were observed between niraparib and
placebo in PR and CR subgroups with respect to patient-reported outcomes.
CONCLUSION Patients achieved clinical benefit from maintenance treatment with niraparib regardless of re-
sponse to the last platinum-based therapy.
J Clin Oncol 37:2968-2973. © 2019 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
Themajority of womenwith advanced ovarian cancer will
experience recurrence after first-line treatment with
platinum-based chemotherapy,1 and recurrent ovarian
cancer is considered incurable.2 After first-line platinum-
based chemotherapy, 70% to 80% of patients with
ovarian cancer have platinum-sensitive disease,1 defined
as having a complete or partial response (CR or PR) to
platinum-based chemotherapy and no progression of
diseasewithin6monthsof thefinal doseof chemotherapy.3
In most cases, successive lines of platinum-based therapy
lead to the development of platinum resistance,1 defined
as an initial response (CR or PR) to platinum-based
chemotherapy with progression less than 6months after
the final dose of chemotherapy.3
Maintenance treatment with a poly(ADP-ribose) po-
lymerase (PARP) inhibitor during the chemotherapy-
free interval is now recommended as a therapeutic
option available to patients with recurrent ovarian
cancer.4,5 Maintenance treatment with PARP in-
hibitors recently has been shown to prolong the
progression-free interval, which allows patients longer
times between chemotherapy regimens.6-8
The National Comprehensive Cancer Network guid-
ance on maintenance therapy originally recom-
mended consideration of maintenance therapy for
patients with a CR, and recurrence therapy was rec-
ommended for patients with a PR (and residual tumor
mass). In 2017, the National Comprehensive Cancer
Network guidelines were updated to include mainte-
nance therapy for patients with a PR as well as those
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with a CR. Since 2016, European Society for Medical On-
cology treatment guidelines have also recommended
maintenance therapy offered to patients with a PR or CR to
platinum-based therapy.4 Although the pivotal phase III
ENGOT-OV16/NOVA trial of niraparib maintenance therapy
enrolled patients with either a PR or CR to platinum-based
chemotherapy,7 no analyses were performed to determine
the effect of response to the last platinum therapy on the
efficacy of niraparib. It is important to understand whether
maintenance therapy with niraparib is of value in patients
with a PR after platinum-based therapy and those with
complete tumor responses.
The objective of this analysis was to assess the safety and
efficacy of niraparib in patients enrolled in the ENGOT-
OV16/NOVA trial on the basis of best response to the last
platinum-based therapy. We also present quality-of-life
(QoL) measures using data from the Functional Assess-
ment of Cancer Therapy–Ovarian (FACT-O) Symptom In-
dex (FOSI) for patients by best response to the last
platinum-based therapy.
PATIENTS AND METHODS
ENGOT-OV16/NOVA (ClinicalTrials.gov identifier:NCT01847274)
was a multicenter, double-blind, randomized, placebo-
controlled, phase III study that enrolled patients with re-
current ovarian cancer. Patients must have completed at
least two previous courses of platinum-containing therapy
before random assignment. For the penultimate platinum-
based chemotherapy regimen, patients must have had
platinum-sensitive disease, defined as achievement of
a response (CR or PR) and no progressive disease within
6 months after completion of the last dose of platinum-
based chemotherapy. For the last platinum-based che-
motherapy regimen, patientsmust have received a platinum-
containing regimen for a minimum of four cycles and
achieved a CR or PR. After the last regimen, patients could
not have had any measurable lesion greater than 2 cm at the
time of study entry.
Patients were assigned to one of two independent cohorts—
germline breast cancer susceptibility gene (BRCA) mutation
(gBRCAmut) or non–gBRCAmut—on the basis of results
TABLE 1. Patient Characteristics at Baseline by Response to the Last Platinum-Based Chemotherapy
Characteristic
gBRCAmut Cohort (n = 203) Non–gBRCAmut Cohort (n = 350)
PR to Last Platinum
(n = 99)
CR to Last Platinum
(n = 104)
PR to Last Platinum
(n = 173)
CR to Last Platinum
(n = 177)
Median (min, max) age, years 60.0 (39, 83) 52.0 (36, 76) 63.0 (33, 83) 63.0 (40, 84)
ECOG performance status
0 62 (62.6) 77 (74.0) 106 (61.3) 132 (74.6)
1 37 (37.4) 27 (26.0) 67 (38.7) 45 (25.4)
Mean (SD) duration of last platinum-based
chemotherapy, months
4.7 (1.95) 4.8 (2.01) 4.7 (1.76) 4.7 (2.09)
Had prior use of bevacizumab 15 (15.2) 35 (33.7) 44 (25.4) 48 (27.1)
Best response to penultimate platinum-based chemotherapy*
PR 40 (40.4) 17 (16.3) 73 (42.2) 23 (13.0)
CR 58 (58.6) 87 (83.7) 99 (57.2) 152 (85.9)
Time to PD after penultimate platinum-based dose, months
6 to , 12 44 (44.4) 36 (34.6) 78 (45.1) 56 (31.6)
$ 12 55 (55.6) 68 (65.4) 95 (54.9) 121 (68.4)
Previous lines of chemotherapy†
2 46 (46.5) 54 (51.9) 100 (57.8) 132 (74.6)
$3 52 (52.5) 50 (48.1) 73 (42.2) 44 (24.9)
Previous lines of platinum-based chemotherapy†
2 53 (53.5) 63 (60.6) 114 (65.9) 147 (83.1)
$ 3 45 (45.5) 41 (39.4) 59 (34.1) 29 (16.4)
NOTE. Data presented are No. (%) of patients unless otherwise noted.
Abbreviations: CR, complete response; ECOG, Eastern Cooperative Oncology Group; gBRCAmut, germline breast cancer susceptibility gene mutation; PD,
progressive disease; PR, partial response; SD, standard deviation.
*Data were missing for one patient with a PR to the last platinum-based therapy in the gBRCAmut cohort, one patient with a PR to the last platinum-based
therapy in the non–gBRCAmut cohort, and two patients with a CR to the last platinum-based therapy in the non–gBRCAmut cohort.
†One patient with a PR to the last platinum-based therapy in the gBRCAmut cohort had only one line of prior chemotherapy, which was platinumbased; one
patient with a CR to the last platinum-based therapy in the non–gBRCAmut cohort had missing data on previous lines of chemotherapy.
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from the BRACAnalysis test (Myriad Genetics, Salt Lake City,
UT) and were randomly assigned 2:1 within each cohort to
receive niraparib 300 mg or placebo once daily until pro-
gression of disease or death. Random assignment occurred
within 8 weeks of the last platinum-based chemotherapy
cycle and was stratified within each cohort according to best
response (CR or PR) to the last platinum-based regimen,
time to progression after completion of the penultimate
platinum-based regimen, and prior use of bevacizumab in
conjunction with at least one prior chemotherapy.
Analyses
Baseline and demographic characteristics were de-
scriptively summarized by cohort (gBRCAmut and non–
gBRCAmut) and best response (PR or CR) to the last
platinum-based therapy. Post hoc efficacy and safety an-
alyses were performed by cohort and best response to the
last platinum-based chemotherapy. Progression-free sur-
vival (PFS) was defined as the time from treatment random
assignment to the earliest date of disease progression or
death as a result of any cause. Disease progression was
assessed by independent radiologic review and central
review by a clinician who was unaware of study group
assignments. PFS was summarized using Kaplan-Meier
methodology. For each subgroup, the hazard ratio (HR)
was estimated along with the two-sided 95% CI using
a stratified Cox proportional hazards model and the strat-
ification factors used in random assignment. The incidence
of adverse events (AEs) was descriptively summarized by
treatment group and best response to the last platinum-
based therapy. No inferential statistics were performed.
Patient-Reported Outcomes
The FOSI questionnaire was used to assess ovarian can-
cer–specific symptoms and QoL. The FOSI is a validated 8-
item measure of symptom response to treatment of ovarian
cancer on the basis of a subset of questions from the FACT-
O questionnaire.9 Patients report their symptom experience
during the past 7 days using a 5-point Likert scale, which
ranges from “not at all” (0) to “very much” (4). The FOSI is
calculated as the total of eight symptoms: pain, fatigue,
nausea, vomiting, bloating, cramping, worry, and QoL. An
Patients were enrolled
(N = 553)
Were receiving ongoing 
treatment at data cutoff
(n = 47)
Were receiving ongoing 
treatment at data cutoff
(n = 46)
Were receiving ongoing 
treatment at data cutoff
(n = 12)
Were receiving ongoing 
treatment at data cutoff
(n = 4)
Discontinued
treatment
Had an adverse
event
Had disease
progression
Requested to stop
treatment
Had other reason
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(n = 63)
(n = 8)
(n = 1)
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Had an adverse
event
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FIG 1. Study enrollment and outcomes. BRCA, breast cancer susceptibility gene. Reprinted with permission.7
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analysis of the change from baseline in overall FOSI score
was performed using a mixed model with treatment, visit,
subgroup, treatment-by-visit interaction, treatment-by-
subgroup interaction, and treatment-by-subgroup-by-visit
interaction as fixed effects and patient as a random effect.
Analyses of the individual symptom-related questions
were also performed. Patients were categorized as
symptomatic if their response was 1 or more and as se-
verely symptomatic if their response was 3 or 4. The
percentages of patients with any symptom and with severe
symptoms were summarized over time by the best re-
sponse (CR or PR) to the last platinum-based chemo-
therapy regimen.
RESULTS
Demographics and Baseline Characteristics
A total of 553 patients were enrolled and randomly assigned
to treatment in the ENGOT-OV16/NOVA trial: 203 in the
gBRCAmut cohort and 350 in the non–gBRCAmut cohort
(Table 1; Fig 1). Topline results have been previously
reported.7 In both cohorts, 49% of patients entered the
study with a PR to their last platinum-based chemotherapy
(Table 1). In the gBRCAmut cohort, patients with a CR
tended to be younger than those with a PR; no difference in
age was noted between patients with a CR and PR in the
non–gBRCAmut cohort. The mean time from completion of
the last dose of platinum-based chemotherapy and random
assignment was 43.2 days for patients with a CR and was
43.8 days for patients with a PR. Within each cohort,
duration of the last platinum-based treatment before ran-
dom assignment was similar among patients with PRs and
CRs. At trial entry, patients with a CR to their last platinum-
based chemotherapy tended to have a better performance
status (Eastern Cooperative Oncology Group performance
status of 0 v 1) than patients with a PR to their last platinum-
based chemotherapy. Patients with a PR to their last
platinum-based therapy had, on average, received more
lines of prior treatment than those with a CR to their last
platinum-based therapy.
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FIG 2. Kaplan-Meier curves for progression-free survival in patients with a partial response (PR) to their last platinum-based therapy in the (A) gBRCAmut
and (B) non-gBRCAmut cohorts, and patients with a complete response (CR) to their last platinum-based therapy in the (C) gBRCAmut and (D) non-
gBRCAmut cohorts. gBRCAmut, germline breast cancer susceptibility gene mutation; HR, hazard ratio.
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Efficacy
Patients who received niraparib derived a significant clin-
ical benefit relative to placebo regardless of the best re-
sponse to the last platinum-based therapy (Fig 2). In the
gBRCAmut cohort, patients with a PR had longer PFS with
niraparib compared with placebo (HR, 0.24; 95%CI, 0.131
to 0.441; P, .0001). Patients with a CR in the gBRCAmut
cohort also had longer PFS with niraparib compared with
placebo (HR, 0.30; 95% CI, 0.160 to 0.546; P, .0001). In
the non–gBRCAmut cohort, patients with a PR (HR, 0.35;
95% CI, 0.230 to 0.532; P, .0001) and patients with a CR
(HR, 0.58; 95% CI, 0.383 to 0.868; P 5 .0082) achieved
a significant benefit with niraparib treatment compared with
placebo.
Safety
Grade 3 or greater AEs that occurred in at least 5% of
patients are summarized in Table 2 by response to the last
platinum-based therapy. The most common grade 3 or
greater AEs among patients with a PR and CR who received
niraparib were, respectively, thrombocytopenia (25.6%
and 31.0%), anemia (26.1% and 23.5%), neutropenia
(10.0% and 12.3%), hypertension (9.4% and 7.0%), and
fatigue (2.8% and 8.6%).
Patient-Reported Outcomes
At the screening assessment, there was no observable
difference in overall FOSI scores between niraparib and
placebo in either of the PR or CR to last platinum-based
therapy subgroups. In patients with a CR, the mean overall
FOSI score at baseline was 25.3 with niraparib and was
25.5 with placebo; in patients with a PR, the score was 25.3
with niraparib and was 24.9 with placebo. Within each
subgroup, no meaningful differences were detected be-
tween niraparib and placebo across time with respect to the
overall FOSI score (Appendix Table A1, online only). Re-
ports of individual symptoms were similar with niraparib
compared with placebo in patients with a PR and with a CR
(Appendix Fig A1, online only). Reports of severe symptoms
remained low in all groups.
DISCUSSION
In the ENGOT-OV16/NOVA trial, niraparib provided clinical
benefit compared with placebo as a maintenance therapy
in patients with platinum-sensitive, recurrent ovarian
cancer who had a response to their last platinum-based
chemotherapy, irrespective of gBRCAmut status.7 Ap-
proximately 50% of patients entered the study with a PR to
their last platinum-based therapy, which is comparable to
rates in other trials of PARP inhibitor maintenance
treatment.6,8 This analysis revealed that patients with a PR
to their last platinum therapy who received niraparib ex-
perienced a PFS benefit relative to placebo. No additional
safety risks were noted for patients with a PR. This suggests
that patients with a PR who discontinue after six courses of
platinum-based chemotherapy are likely to derive benefit
from maintenance treatment with niraparib.
Patient-reported symptoms were comparable between
niraparib and placebo at screening and on study regardless
of responses to the last platinum-based therapy. For both
subgroups, overall mean FOSI scores were similar between
treatments. Symptoms such as pain, fatigue, and nausea
remained stable or improved with time during the study.
The proportion of patients who reported any-grade or se-
vere vomiting remained low. The proportion of patients who
experienced other symptoms, such as worry, bloating, and
cramps, remained relatively stable throughout the study.
The data presented herein demonstrate that niraparib
provides benefit to patients with a PR with a tolerable safety
profile and maintained QoL during treatment.10 Because
safety is an important consideration for patients with ad-
vanced ovarian cancer, the outcome of this analysis con-
firms the utility of niraparib maintenance therapy in patients
with a PR to their last platinum-based therapy.4,5
In summary, our analysis provides evidence to support the
use of maintenance therapy with niraparib in patients with
a PR to their last platinum-based therapy, because they
derive a PFS benefit from niraparib maintenance therapy.
TABLE 2. Grade 3 or Greater AEs That Occurred in at Least 5% of Patients by Response to the Last Platinum-Based Chemotherapy
AE
No. (%) of Patients
Overall With PR to Last Platinum With CR to Last Platinum
Niraparib
(n = 367)
Placebo
(n = 179)
Niraparib
(n = 180)
Placebo
(n = 88)
Niraparib
(n = 187)
Placebo
(n = 91)
Thrombocytopenia 104 (28.3) 1 (0.6) 46 (25.6) 0 58 (31.0) 1 (1.1)
Anemia 91 (24.8) 0 47 (26.1) 0 44 (23.5) 0
Neutropenia 41 (11.2) 1 (0.6) 18 (10.0) 0 23 (12.3) 1 (1.1)
Hypertension 30 (8.2) 4 (2.2) 17 (9.4) 2 (2.3) 13 (7.0) 2 (2.2)
Fatigue 21 (5.7) 0 5 (2.8) 0 16 (8.6) 0
Abbreviations: AE, adverse event; CR, complete response; PR, partial response.
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APPENDIX
TABLE A1. Change From Baseline in FOSI Score
Response to Last Platinum Cycle
No. of Patients
Niraparib-Placebo LS Mean (95% CI)Niraparib Placebo
Complete response 2 151 75 20.7 (21.76 to 0.35)
4 137 70 20.2 (21.26 to 0.90)
6 119 56 1.2 (0.02 to 2.33)
8 99 40 0.2 (21.11 to 1.47)
10 87 30 0.9 (20.52 to 2.33)
12 78 29 0.4 (21.08 to 1.86)
14 63 22 1.1 (20.45 to 2.74)
Partial response 2 144 77 20.6 (21.68 to 0.43)
4 122 50 0.6 (20.55 to 1.81)
6 100 30 0.7 (20.71 to 2.09)
8 89 17 1.0 (20.71 to 2.72)
10 71 10 20.1 (22.22 to 2.06)
12 69 7 0.7 (21.77 to 3.16)
14 57 4 1.7 (21.42 to 4.83)
NOTE. Obtained from mixed model of the change from baseline with treatment, visit, subgroup, treatment-by-visit, treatment-by-subgroup,
and treatment-by-subgroup-by-visit as fixed effects and patient as a random effect.
Abbreviations: FOSI, Functional Assessment of Cancer Therapy–Ovarian Symptom Index; LS, least-squares.
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FIG A1. Individual FOSI measures over time by best response to last platinum. BL, baseline; CR, complete response; PR, partial response.
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FIG A1. (Continued).
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